A Long-Term Vision for Advanced Therapeutics
At Olon, innovation doesn’t just happen in the laboratory — it’s built into every stage of the company’s growth strategy. Following a strong year of global engagement and cross-divisional alignment, the organization is now channeling significant investment toward new capabilities in high-potency manufacturing and bioconjugation — two critical technologies shaping the future of complex therapeutics.
Many of the efforts we have taken over the last year will help define this next chapter, as these investments represent a coordinated global effort across Olon’s network of 13 manufacturing facilities in addition to our U.S. operations, expand technical depth, ensure compliance with the most stringent containment standards, and meet the growing market demand for highly specialized drug substances.
Meeting Market Demand for High-Potency Manufacturing
The pipeline of oncology and targeted small-molecule drugs continues to grow, driving unprecedented demand for HPAPI (Highly Potent Active Pharmaceutical Ingredient) capabilities. Olon’s R&D and engineering teams are responding through a combination of new containment infrastructure, advanced analytical support, and enhanced training programs across multiple global sites.
These initiatives are designed to strengthen Olon’s ability to safely develop and manufacture compounds with occupational exposure limits (OELs) below 1 µg/m³, while maintaining the flexibility to scale from clinical to commercial production. In practice, that means greater efficiency, stronger alignment with client safety protocols, and a faster path from process development to GMP manufacturing.
Advancing Bioconjugation and ADC Technologies
At the same time, Olon is advancing into one of the most promising frontiers in modern drug development: bioconjugation and Antibody–Drug Conjugates (ADC) development and manufacturing. The company’s scientists and engineers are applying their process chemistry and biologics interface expertise to build robust, compliant capabilities for linker chemistry, payload and payload-linkers synthesis and conjugation technologies.
These efforts are part of a multi-year innovation roadmap positioning Olon as a full-spectrum CDMO partner for emerging therapeutic modalities, from traditional APIs to complex hybrid molecules that bridge chemistry and biology.
A Unified Global Platform
Olon’s expansion in these high-value areas underscores a defining theme for the company in 2025 and beyond: unification and integration. Olon Group and Olon USA are operating in closer alignment than ever before, leveraging a shared technical culture, common quality standards, and synchronized global project management to deliver seamless support to clients worldwide.
This unified model allows pharmaceutical partners to work with a single, trusted CDMO while accessing the full scale, safety, and specialization of Olon’s global network, whether their projects begin in early-stage development, scale-up, or commercial supply.
Building Toward Tomorrow
As these strategic investments take shape through 2026, Olon’s message remains clear: the company is investing not only in facilities and technologies, but in the scientific partnerships that define the next generation of medicines.
Olon’s continuous commitment to quality, innovation, and safety ensures that its partners can move confidently into an increasingly complex therapeutic landscape, supported by a CDMO ready for the future.
Follow Olon’s journey as we expand our capabilities and continue to invest in the future of advanced pharmaceutical manufacturing. Visit www.olonspa.com for the latest updates.